Dr. Brown on the Utility of PARP Inhibitors in Recurrent Platinum-Sensitive Ovarian Cancer

Partner | Cancer Centers | <b>Atrium Health Levine Cancer Institute</b>

Jubilee Brown, MD, discusses the utility of PARP inhibitors in patients with recurrent platinum-sensitive ovarian cancer.

Jubilee Brown, MD, professor, director, Gynecologic Oncology, Levine Cancer Institute, Atrium Health, discusses the utility of PARP inhibitors in patients with recurrent platinum-sensitive ovarian cancer.

As PARP inhibitor use increases, there is growing evidence that sensitivity to these agents is similar to platinum sensitivity, according to Brown. Moreover, studies such as the phase 3 ARIEL3 trial (NCT01968213) have demonstrated the benefit of using PARP inhibitors in patients who are platinum sensitive in the recurrent setting, Brown explains.

The studies incorporating PARP inhibitors have shown an improvement in progression-free survival, and the use of these agents is no longer exclusive to the up-front maintenance setting, Brown concludes.